Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Robin K. Nielsen"'
Autor:
James F. Cummings, Birgitte Giersing, W. Ripley Ballou, David E. Lanar, Elissa Malkin, Christian F. Ockenhouse, Kathryn Tucker, Filip Dubovsky, V. Ann Stewart, Mark E. Polhemus, Robin K. Nielsen, Megan Dowler, Marie-Claude Dubois, D. Gray Heppner, Robert Schwenk, Joe Cohen, Jack Williams, Laure Y. Juompan, Collette J. Hillier, Christine Prosperi, Kent E. Kester, Lisa A. Ware, Douglas S. Walsh, In-Kyu Yoon, B. Ted Hall, Urszula Krzych, Michele D. Spring
Publikováno v:
Vaccine. 28:5135-5144
Plasmodium falciparum Liver Stage Antigen 1 (LSA-1) is a pre-erythrocytic stage antigen. Our LSA-1 vaccine candidate is a recombinant protein with full-length C- and N-terminal flanking domains and two of the 17 amino acid repeats from the central re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e10eb21d2d3990dda9655444fa522891
https://doi.org/10.1016/j.vaccine.2009.08.046
https://doi.org/10.1016/j.vaccine.2009.08.046
Autor:
James F, Cummings, Melanie L, Guerrero, James E, Moon, Paige, Waterman, Robin K, Nielsen, Stacie, Jefferson, F Liaini, Gross, Kathy, Hancock, Jacqueline M, Katz, Vidadi, Yusibov, Stephen J, Streatfield
Publikováno v:
Vaccine
Background Novel influenza viruses continue to pose a potential pandemic threat worldwide. In recent years, plants have been used to produce recombinant proteins, including subunit vaccines. A subunit influenza vaccine, HAC1, based on recombinant hem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d9342e3224a24b655cdd644530e8ef8
https://pubmed.ncbi.nlm.nih.gov/24126211
https://pubmed.ncbi.nlm.nih.gov/24126211
Autor:
Kent E. Kester, A.C. Whelen, Jackie Williams, Jonathan D. Berman, Kevin C. Kain, Robin K. Nielsen, Moshe J. Shmuklarsky, Jeffrey D. Chulay, Megan Dowler
Publikováno v:
Transactions of the Royal Society of Tropical Medicine and Hygiene. 95(4)
Plasmodia infect the liver for about 7 days before subsequently infecting the blood. Present prophylaxis against Plasmodium falciparum malaria employs agents that primarily kill blood stages and must be continued for 28 days after the last exposure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39986ccaa709c7d30d473f2afb080330
https://pubmed.ncbi.nlm.nih.gov/11579890
https://pubmed.ncbi.nlm.nih.gov/11579890